My thesis is about soft tissue neoplastic diseases which have significant therapeutic challenges due to their heterogeneity and limited responsiveness to single treatment. This is why complex treatment including surgery, radiotherapy, and systemic pharmacotherapy are required to achieve disease control. From pharmacological perspective, antineoplastic drugs act through diverse mechanisms, including DNA damage, disruption of cell cycle, inhibition of angiogenesis and signaling pathways. However, the efficacy is limited by the drug resistance, cumulative toxicity, and drug-drug interactions. These factors make us necessary to do careful drug selection, sequencing, and monitoring. As a consequence, pharmacology plays a central role in optimizing treatment and improving clinical outcomes in patients with soft tissue neoplastic diseases.